NSE · PAR
Par Drugs & Chemicals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹103 Cr with net profit ₹13 Cr — a 12.95% net margin, versus 15.12% the period before.
Shareholding
As of 2026-06-30
- Promoter73.41%
- Public26.51%
- DII0.09%
12,782 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.31× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #13 of 15 by market cap · medians across 14 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Astrazeneca Pharma India Ltd. | ₹17,165 Cr | 98.95 | 19.67 | 21.49% | 6.97% |
| Alivus Life Sciences Ltd. | ₹17,065 Cr | 27.45 | 5.12 | 16.94% | 23.28% |
| Akums Drugs & Pharmaceuticals Ltd. | ₹11,793 Cr | 38.62 | 3.56 | 7.7% | 6.48% |
| Procter & Gamble Health Limited | ₹9,005 Cr | 27.03 | 17.17 | 62.32% | 24.91% |
| Gujarat Themis Biosyn Ltd. | ₹5,601 Cr | 119.87 | 7.4 | — | 25.04% |
| Jagsonpal Pharmaceuticals Ltd. | ₹1,533 Cr | 32.59 | 5.55 | 15.6% | 15.47% |
| Bajaj HealthCare Limited | ₹1,122 Cr | 19.93 | 2.11 | 8.81% | 2.81% |
| Anuh Pharma Limited | ₹921 Cr | 20.84 | 2.61 | 11.65% | 5.67% |
| Amanta Healthcare Limited | ₹784 Cr | 51.08 | 3.56 | 7.46% | 5.04% |
| Bafna Pharmaceuticals Ltd. | ₹728 Cr | 93.5 | 7.57 | 11.54% | 5.46% |
| Par Drugs & Chemicals Ltd.(this company) | ₹174 Cr | 11.98 | 1.55 | 11.71% | 13.31% |
AI analysis
AI-generated · google/gemini-2.5-flashPar Drugs & Chemicals Ltd. has a market capitalization of Rs 126 Cr. The company reported revenue of Rs 103.12 Cr and a profit margin of 12.65%. The Price-to-Earnings (PE) ratio is 148.65, with an EPS of 10.65. The book value stands at Rs 91.01. Return on Equity (ROE) is 11.71% and Return on Capital Employed (ROCE) is 15.56%. The company has no debt, with a debt-to-equity ratio of 0. The 52-week high for the share price was Rs 122.43 and the 52-week low was Rs 78.05.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Promoter holding is high at 73.41% as of Mar 2026.
- +There are no shares pledged by the promoters.
- +Net profit has increased from Rs 11.61 Cr in Mar 2021 to Rs 13.36 Cr in Mar 2025.
Negatives
- −The Price-to-Earnings (PE) ratio of 148.65 is high relative to its EPS of 10.65.
- −Revenue growth information was not provided in the data.
- −Net profit decreased in the latest quarter from Rs 4.8 Cr in Dec 2025 to Rs 0.85 Cr in Mar 2026.
- −EPS decreased from Rs 11.78 in Mar 2024 to Rs 10.86 in Mar 2025.
- −No DII or FII shareholding has been reported as of Mar 2026.
Financial Performance
Par Drugs & Chemicals Ltd. reported revenue of Rs 103.12 Cr in the latest fiscal year (Mar 2025). Net profit for the same period was Rs 13.36 Cr. Over the past five years, annual revenue has grown from Rs 60.94 Cr in Mar 2021 to Rs 103.12 Cr in Mar 2025. Similarly, net profit increased from Rs 11.61 Cr in Mar 2021 to Rs 13.36 Cr in Mar 2025. The company's highest EPS was Rs 18.87 in Mar 2021.
Profitability & Returns
The company's profit margin is 12.65% based on the latest available data. Return on Equity (ROE) is 11.71%, indicating the return generated on shareholders' capital. Return on Capital Employed (ROCE) is 15.56%, reflecting the efficiency of capital utilization. The EPS for the latest fiscal year (Mar 2025) was Rs 10.86, showing a decrease from Rs 11.78 in Mar 2024.
Balance Sheet
Par Drugs & Chemicals Ltd. has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 91.01. The company has maintained a healthy financial structure with no pledges by promoters on their shareholding. This suggests a strong capital structure with reliance on equity funding.
Ownership & Pledges
As of March 2026, promoter holding in Par Drugs & Chemicals Ltd. stands at 73.41%. Public shareholding is 26.59%. There is no FII or DII holding reported. The number of shareholders increased significantly from 289 in Mar 2021 to 13,222 in Mar 2026. The promoters have not pledged any of their shares.
Regulatory & Surveillance
No information regarding surveillance measures for Par Drugs & Chemicals Ltd. was provided in the data. The company has reported quarterly results through Mar 2026. The latest quarterly net profit was Rs 0.85 Cr in Mar 2026, a decrease from Rs 4.8 Cr in Dec 2025.
Data as of — price: 2026-09-10 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Par Drugs & Chemicals Ltd.share price & fundamentals